Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. John's wort complications

This article was originally published in The Tan Sheet

Executive Summary

U.K. Committee on the Safety of Medicines' Feb. 29 statement warning against taking St. John's wort with 17 Rx drugs, including Celexa, Prozac, Zoloft and Imitrex, is brought to FDA's attention by Public Citizen's Health Research in a March 2 letter. FDA's recent warnings concerning the herbal's effects on certain antiretroviral AIDS drugs is an "insufficient response to a serious public health hazard," the consumer group says, urging the agency to "immediately issue a warning to American physicians and patients about all of these drugs and require warnings be included in [their] labeling" regarding their potential interaction with St. John's wort
Advertisement

Related Content

St. John's Wort, Rx Drug Use Warning Adopted By CHPA
St. John's Wort, Rx Drug Use Warning Adopted By CHPA
St. John's Wort, Rx Drug Use Warning Adopted By CHPA

Topics

Advertisement
UsernamePublicRestriction

Register

PS090940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel